rss
Sex Transm Infect 2001;77:409-412 doi:10.1136/sti.77.6.409

Podophyllin office therapy against condyloma should be abandoned

  1. Geo von Krogh1,
  2. Eric Longstaff2
  1. 1Department of Dermatovenereology, Karolinska Hospital, 17176, Stockholm, Sweden
  2. 2Pre-clinical Development Services Ltd, Stockport, UK
  1. Dr von Krogh geo.von.krogh{at}ood.ki.se
  • Accepted 22 May 2001

Abstract

Podophyllin, a crude plant extract with low efficacy, high toxicity, and a serious mutagenicity profile does not comply with the WHO guidelines for plant derived treatments and should be removed from clinical treatment protocols. Home treatment with pharmaceutical products based on podophyllotoxin—the purified, standardised active antiwart ingredient of podophyllin—represents safe and effective first line therapy for patients with anogenital warts.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.